After consulting FDA STeP and signing an NDA with UL, the top FDA certified consulting firm, on November 25, 2022, after contacting with a networked distributor with company L for about a month after providing company product information and FDA STeP data, we proposed an appropriate distributor for the entire US market and GSA and VA.
Company L's U.S. officials informed us that large-scale distributors who will cover the entire U.S. and the Public Procurement Service (GSA) and Veterans Hospital (VA) are interested in Anyfusion U.S. copyright. According to L company's proposal for this contract, L company will provide tangible results to the company from February to March 2023, meet the necessary conditions for entering the U.S. market, and proceed with a final contract with a distributor that meets the company's conditions. After FDA 510K certification, we will consult with our contracting U.S. partner and supply it to the market from the second half of next year, and we will change the market with an Anyfusion cylinder pump that suits the U.S. market.
The U.S. Procurement Market and Veterans Hospital are the best healthcare-seeking institutions in the U.S., and the equipment used in these institutions must be guaranteed the highest reliability and is expected to have a positive impact on the spread to all hospitals in the U.S. To gain credibility in the U.S. market is to gain credibility in the global market, and we will do our best in cooperation with reading officials to become a global product with the best quality and service as well as perfect products.
In order to use it universally in the U.S. market, it has to be listed on the U.S. Medicare, Medicaid, The Affordable Care Act, and private insurance, and Company L has decided to help.
Just as we have overcome many difficulties in developing Anyfusion with original technology, registering items by the Ministry of Food and Drug Safety, separately calculating by the Health Insurance Review and Assessment Service, selecting FDA STeP, and expanding the use of domestic hospitals, we will overcome all difficulties.
Exclusive supply negotiations with Saudi Arabia, Iran and Kuwait are scheduled at the Dubai International Arab Health Exhibition in the UAE from January 30 to February 2, 2023. The Middle East market is also expected to have a significant impact on the U.S. market situation, and we will do our best to target the Middle East market, which is rapidly emerging with oil money, and we will draw tangible contract negotiations at this exhibition.
 
Thank you.